Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Locus Biosciences

Main focus: New treatments against bacterial infections

Company stage: Clinical

Diseases: Urinary tract infection, other infections

Genome editing tool: CRISPR-Cas3

Funding stage: Private

Location: North Carolina, USA

Website: https://www.locus-bio.com/

Partners: Janssen Pharma

Locus Biosciences is a clinical-stage gene-editing company focused on treating bacterial infectious diseases. The company uses its next generation sequencing-based platform to rapidly identify new bacterial targets and phages. Locus uses CRISPR-Cas3 crPhages as the base of their therapies. The phages are designed using machine learning in order to optimise effectiveness against new bacterial targets.

LOCUS Biosciences, Inc.

Press Releases

Related News and Updates

Job Opportunities

Clinical Trials

Pre-clinical Trials

Stocks and Markets

Diseases

Webinar

Your Latest CMN News

CMN Weekly (20 June 2025) - Your Weekly CRISPR...

CMN Weekly

Jun. 20, 2025

Some of the best links we picked up around the internet

Intellia Reports Positive Three-Year Follow-up...

CMN Clinical

Jun. 18, 2025

Intellia Therapeutics has reported positive three-year follow-data from the ongoing Phase 1/2 trial of lonvo-z (formerly known as NTLA-2002) in...

Eli Lilly to Acquire Verve Therapeutics to Advance...

CMN Briefs

Jun. 17, 2025

Eli Lilly announced today that it will acquire Verve Therapeutics for up to $1.3 billion to develop single-dose base-editing treatments for people...

Hydrogel enhances CRISPR-mediated tumour targeting

CMN Special

Jun. 16, 2025

Chinese researchers have developed a thermosensitive, polyamine-modified hydrogel that significantly improves the co-delivery of CRISPR/Cas9 gene...

CMN Weekly (13 June 2025) - Your Weekly CRISPR...